Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Roland Kontermann. (2012) Dual targeting strategies with bispecific antibodies. mAbs 4:2, pages 182-197.
Read now
Read now
Articles from other publishers (47)
Masoud Mohammad Mirzapour, Majid Farshdousti Hagh, Faroogh Marofi, Saeed Solali & Arsalan Alaei. (2023) Investigating the synergistic potential of TRAIL and SAHA in inducing apoptosis in MOLT-4 cancer cells. Biochemical and Biophysical Research Communications 676, pages 13-20.
Crossref
Crossref
Narjes Jafari, Saeid Abediankenari & Hadi Hossein-Nataj. (2021) miR-34a mimic or pre-mir-34a, which is the better option for cancer therapy? KatoIII as a model to study miRNA action in human gastric cancer cells. Cancer Cell International 21:1.
Crossref
Crossref
Anais Blanchet, Agathe Bourgmayer, Jean-Emmanuel Kurtz, Georg Mellitzer & Christian Gaiddon. (2021) Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair. Cancers 13:4, pages 916.
Crossref
Crossref
Aaron R. J. Hutton, Maelíosa T. C. McCrudden, Eneko Larrañeta & Ryan F. Donnelly. (2020) Influence of molecular weight on transdermal delivery of model macromolecules using hydrogel-forming microneedles: potential to enhance the administration of novel low molecular weight biotherapeutics. Journal of Materials Chemistry B 8:19, pages 4202-4209.
Crossref
Crossref
Maha S. Al-Keilani & Nour A. Al-Sawalha. (2017) Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms. Chemical Research in Toxicology 30:10, pages 1767-1777.
Crossref
Crossref
Yutaka Okagawa, Kohichi Takada, Yohei Arihara, Shohei Kikuchi, Takahiro Osuga, Hajime Nakamura, Yusuke Kamihara, Naotaka Hayasaka, Makoto Usami, Kazuyuki Murase, Koji Miyanishi, Masayoshi Kobune & Junji Kato. (2016) Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells. PLOS ONE 11:12, pages e0168355.
Crossref
Crossref
Helena Verdaguer, Josep Tabernero & Teresa Macarulla. (2016) Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology 8:3, pages 230-242.
Crossref
Crossref
R. A. Kovalev, T. A. Shtam, D. V. Karelov, V. S. Burdakov, A. V. Volnitskiy, E. M. Makarov & M. V. Filatova. (2015) Histone deacetylase inhibitors cause TP53-dependent induction of p21/Waf1 in tumor cells with TP53 mutations. Cell and Tissue Biology 9:3, pages 191-197.
Crossref
Crossref
Shane O’Grady & Matthew W. Lawless. 2015. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
269
288
.
Mohsin Ahmad Khan, Faidad Khan, Nadeem Ahmad, Muhammad Islam Khan, Ahmad Usman Zafar & Tayyab Husnain. (2014) Expression line approach to recombinant human epidermal growth factor into the yeast, Pichia pastoris from Huh-7 cell line. Molecular Biology Reports 41:3, pages 1445-1451.
Crossref
Crossref
Wenjun Jiang, Qiya Guo, Jun Wu, Bin Guo, Yingming Wang, Shenan Zhao, Huiling Lou, Xin Yu, Xinyu Mei, Chaoqun Wu, Shouyi Qiao & Yanhua Wu. (2012) Dual effects of sodium butyrate on hepatocellular carcinoma cells. Molecular Biology Reports 39:5, pages 6235-6242.
Crossref
Crossref
Daniel S. Chen. 2012. Targeted Therapeutics in Melanoma. Targeted Therapeutics in Melanoma
155
184
.
Yan‐Shen Shan, Jung‐Hua Fang, Ming‐Derg Lai, Meng‐Chi Yen, Pin‐Wen Lin, Hui‐Ping Hsu, Chian‐Yuh Lin & Yi‐Ling Chen. (2010) Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules. Molecular Carcinogenesis 50:10, pages 739-750.
Crossref
Crossref
Tommaso Iannitti & Beniamino Palmieri. (2012) Clinical and Experimental Applications of Sodium Phenylbutyrate. Drugs in R&D 11:3, pages 227-249.
Crossref
Crossref
Roland E. Kontermann. 2011. Bispecific Antibodies. Bispecific Antibodies
1
28
.
Haiyan Guo, Yukti Choudhury, Jing Yang, Can Chen, Felix Chang Tay, Tit Meng Lim & Shu Wang. (2010) Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate. The Journal of Gene Medicine 13:1, pages 26-36.
Crossref
Crossref
Dafne Müller & Roland E. Kontermann. (2010) Bispecific Antibodies for Cancer Immunotherapy. BioDrugs 24:2, pages 89-98.
Crossref
Crossref
Luc Gailhouste, Frédéric Ezan, Anne Bessard, Christophe Frémin, Julie Rageul, Sophie Langouët & Georges Baffet. (2009)
RNAi‐mediated MEK1 knock‐down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth
in vitro
and
in vivo
. International Journal of Cancer 126:6, pages 1367-1377.
Crossref
Crossref
Mats Ljungman. (2009) Targeting the DNA Damage Response in Cancer. Chemical Reviews 109:7, pages 2929-2950.
Crossref
Crossref
Dana D. Hu-Lowe, Helen Y. Zou, Maren L. Grazzini, Max E. Hallin, Grant R. Wickman, Karin Amundson, Jeffrey H. Chen, David A. Rewolinski, Shinji Yamazaki, Ellen Y. Wu, Michele A. McTigue, Brion W. Murray, Robert S. Kania, Patrick O'Connor, David R. Shalinsky & Steve L. Bender. (2008) Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research 14:22, pages 7272-7283.
Crossref
Crossref
M K Robinson, K M Hodge, E Horak, Å L Sundberg, M Russeva, C C Shaller, M von Mehren, I Shchaveleva, H H Simmons, J D Marks & G P Adams. (2008) Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. British Journal of Cancer 99:9, pages 1415-1425.
Crossref
Crossref
Somdutta Roy, Randy Jeffrey & Martin Tenniswood. (2008) Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Molecular Cancer Therapeutics 7:7, pages 1931-1939.
Crossref
Crossref
Yasushi Sasaki, Hideaki Negishi, Masashi Idogawa, Hiromu Suzuki, Hiroaki Mita, Minoru Toyota, Yasuhisa Shinomura, Kohzoh Imai & Takashi Tokino. (2008) Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. Molecular Cancer Therapeutics 7:4, pages 779-787.
Crossref
Crossref
Andrea Brioschi, Gian Zara, Sara Calderoni, Maria Gasco & Alessandro Mauro. (2008) Cholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug. Molecules 13:2, pages 230-254.
Crossref
Crossref
M Reboredo, M Zabala, I Mauleon, J De Las Rivas, F Kreppel, S Kochanek, J Prieto, R Hernandez-Alcoceba & M G Kramer. (2007) Interleukin-12 inhibits liver-specific drug-inducible systems in vivo. Gene Therapy 15:4, pages 277-288.
Crossref
Crossref
Nima Khalighinejad, Hesammodin Hariri, Omid Behnamfar, Arash Yousefi & Amir Momeni. (2008) Adenoviral gene therapy in gastric cancer: A review. World Journal of Gastroenterology 14:2, pages 180.
Crossref
Crossref
S. Choi & J.N. Myers. (2008) Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy. Journal of Dental Research 87:1, pages 14-32.
Crossref
Crossref
Peter Bohlen, Zhenping Zhu & Daniel J. Hicklin. 2008. Tumor Angiogenesis. Tumor Angiogenesis
425
452
.
Liangfeng Han, Annaka M. Lorincz & Saraswati Sukumar. 2008. Antiangiogenic Agents in Cancer Therapy. Antiangiogenic Agents in Cancer Therapy
331
349
.
Roya Khosravi-Far & Eileen WhiteSharmila Shankar & Rakesh K. Srivastava. 2008. Programmed Cell Death in Cancer Progression and Therapy. Programmed Cell Death in Cancer Progression and Therapy
261
298
.
Roya Khosravi-Far & Eileen WhiteKageaki Kuribayashi & Wafik S. El-Deiry. 2008. Programmed Cell Death in Cancer Progression and Therapy. Programmed Cell Death in Cancer Progression and Therapy
201
221
.
V. P. Almazov, D. V. Kochetkov & P. M. Chumakov. (2007) Use of p53 for therapy of human cancer. Molecular Biology 41:6, pages 863-877.
Crossref
Crossref
Zhi-qun WU, Rui ZHANG, Chao Connie, Ji-feng ZHANG & Yuan-qiang ZHANG. (2007) Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell. Chinese Medical Journal 120:23, pages 2112-2118.
Crossref
Crossref
Guo-min ZHANG, Yü-ping CHEN, Yuan-zhi GUAN, Yan WANG & Yun-qing AN. (2007) Modification and identification of a vector for making a large phage antibody library. Chinese Medical Journal 120:22, pages 2011-2016.
Crossref
Crossref
Paraskevi Vogiatzi, Carla Vindigni, Franco Roviello, Alessandra Renieri & Antonio Giordano. (2007) Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. Journal of Cellular Physiology 211:2, pages 287-295.
Crossref
Crossref
Merrill E. Goldsmith, Alian Aguila, Kenneth Steadman, Alfredo Martinez, Seth M. Steinberg, Michael C. Alley, William R. Waud, Susan E. Bates & Tito Fojo. (2007) The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Molecular Cancer Therapeutics 6:2, pages 496-505.
Crossref
Crossref
Sharmila Shankar & Rakesh K. Srivastava. 2007. Apoptosis, Cell Signaling, and Human Diseases. Apoptosis, Cell Signaling, and Human Diseases
335
361
.
Sharmila Shankar & Rakesh K. Srivastava. 2007. Apoptosis, Cell Signaling, and Human Diseases. Apoptosis, Cell Signaling, and Human Diseases
219
261
.
Christoph Wissmann & Michael Detmar. (2006) Pathways Targeting Tumor Lymphangiogenesis: Fig. 1.. Clinical Cancer Research 12:23, pages 6865-6868.
Crossref
Crossref
Rebecca L. Rich & David G. Myszka. (2006) Survey of the year 2005 commercial optical biosensor literature. Journal of Molecular Recognition 19:6, pages 478-534.
Crossref
Crossref
Ana R. Quesada, Ramón Muñoz-Chápuli & Miguel A. Medina. (2006) Anti-angiogenic drugs: from bench to clinical trials. Medicinal Research Reviews 26:4, pages 483-530.
Crossref
Crossref
M G Achen, G B Mann & S A Stacker. (2006) Targeting lymphangiogenesis to prevent tumour metastasis. British Journal of Cancer 94:10, pages 1355-1360.
Crossref
Crossref
Juqun Shen, Marie Danielle Vil, Xenia Jimenez, Michelle Iacolina, Haifan Zhang & Zhenping Zhu. (2006) Single Variable Domain-IgG Fusion. Journal of Biological Chemistry 281:16, pages 10706-10714.
Crossref
Crossref
Naren Gupta, Pamela M. Martin, Puttur D. Prasad & Vadivel Ganapathy. (2006) SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sciences 78:21, pages 2419-2425.
Crossref
Crossref
Robert D. Loberg, Christopher J. Logothetis, Evan T. Keller & Kenneth J. Pienta. (2005) Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype. Journal of Clinical Oncology 23:32, pages 8232-8241.
Crossref
Crossref
Stanley G. Rockson. (2005) Literature Watch. Lymphatic Research and Biology 3:3, pages 167-171.
Crossref
Crossref
Philipp Holliger & Peter J Hudson. (2005) Engineered antibody fragments and the rise of single domains. Nature Biotechnology 23:9, pages 1126-1136.
Crossref
Crossref